Weight Loss — clinical cases
29 questions
Sample cases
- Case 1
A 52-year-old woman has a BMI of 28.4 kg/m², hypertension controlled on amlodipine, and prediabetes (HbA1c 6.1%). She has been following a reduced-calorie diet and walking daily for 4 months and asks whether a medication could help. Which statement about her eligibility for obesity pharmacotherapy is correct?
- A.She is eligible now: BMI ≥27 kg/m² with an adiposity-related complication, used together with health behaviour changes
- B.She is not eligible until her BMI reaches 30 kg/m², whatever complications she has
- C.She is not eligible until her BMI reaches 35 kg/m², the threshold for medication in people with complications
- D.She is eligible only after failing a supervised 12-month diet program, then for medication alone
- Case 2
A 45-year-old woman of South Asian descent has a BMI of 26.5 kg/m², a waist circumference of 92 cm, and prediabetes (HbA1c 6.2%). According to the 2025 Canadian Adult Obesity Clinical Practice Guideline, what should guide the decision to start obesity pharmacotherapy?
- A.The standard BMI threshold of ≥27 kg/m² with a complication, applied the same way regardless of ethnicity
- B.Waist circumference with sex- and ethnicity-specific cut-offs, plus ethnicity-specific BMI and complications
- C.A body-fat percentage measured by dual-energy X-ray absorptiometry, which must exceed a sex-specific cut-off
- D.BMI alone, because waist circumference has not been validated for guiding drug therapy decisions
- Case 3
A 38-year-old woman with a BMI of 34 kg/m² wants to start an obesity medication. Her father was treated for medullary thyroid carcinoma. She has no seizure history, her blood pressure is 124/78 mmHg, and she takes no other medications. Which medication is contraindicated for her?
- A.Orlistat 120 mg orally three times daily
- B.Naltrexone/bupropion ER 16 mg/180 mg twice daily
- C.Semaglutide 2.4 mg subcutaneously weekly
- D.Metformin 500 mg orally twice daily
